Hengrui partners X-Body to bring AMD antibody to China
This article was originally published in Scrip
Executive Summary
Few Chinese pharmaceutical companies are capable of independently developing novel antibodies, which require costly equipment, skilled employees and investment in R&D. But Jiangsu Hengrui Medicine, a major Chinese firm based in Lianyungang, has decided to take the plunge through a new partnership with the US therapeutic antibody developer X-Body Biosciences, with an eye on the growing Chinese market for age-related macular degeneration (AMD).